Acelyrin boosts immunology pipeline through acquisition of ValenzaBio
Acelyrin has acquired ValenzaBio, a privately held clinical-stage biopharmaceutical company, in an all-stock deal. With the acquisition of ValenzaBio, the US- based late-stage clinical biopharma company, anticipates to add multiple clinical and pre-clinical development programs to its immunology pipeline, including a potentially differentiated therapeutic for the treatment of thyroid eye disease. Acelyrin’s immunology portfolio is […]